1. Home
  2. KELYA vs LCTX Comparison

KELYA vs LCTX Comparison

Compare KELYA & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kelly Services Inc.

KELYA

Kelly Services Inc.

HOLD

Current Price

$15.25

Market Cap

340.1M

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.11

Market Cap

301.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KELYA
LCTX
Founded
1946
1990
Country
United States
United States
Employees
4900
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
340.1M
301.7M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
KELYA
LCTX
Price
$15.25
$1.11
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
$15.00
$6.25
AVG Volume (30 Days)
336.7K
959.1K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
3.07%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$14,556,000.00
Revenue This Year
N/A
$109.40
Revenue Next Year
$4.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
53.24
52 Week Low
$7.98
$0.97
52 Week High
$17.75
$2.09

Technical Indicators

Market Signals
Indicator
KELYA
LCTX
Relative Strength Index (RSI) 64.45 46.48
Support Level $8.48 $1.00
Resistance Level $16.20 $1.32
Average True Range (ATR) 0.66 0.06
MACD -0.12 0.01
Stochastic Oscillator 33.85 72.22

Price Performance

Historical Comparison
KELYA
LCTX

About KELYA Kelly Services Inc.

Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Share on Social Networks: